Emergent Biosolutions, Inc. (EBS) Holdings Boosted by Northern Trust Corp
Northern Trust Corp raised its position in Emergent Biosolutions, Inc. (NYSE:EBS) by 47.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 906,731 shares of the biopharmaceutical company’s stock after purchasing an additional 290,863 shares during the quarter. Northern Trust Corp owned about 2.21% of Emergent Biosolutions worth $30,747,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of EBS. Vanguard Group Inc. boosted its holdings in Emergent Biosolutions by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock valued at $109,574,000 after purchasing an additional 238,194 shares during the last quarter. State Street Corp raised its stake in shares of Emergent Biosolutions by 17.2% in the 1st quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock valued at $42,180,000 after acquiring an additional 213,500 shares during the period. Rice Hall James & Associates LLC raised its stake in shares of Emergent Biosolutions by 26.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 669,617 shares of the biopharmaceutical company’s stock valued at $22,707,000 after acquiring an additional 138,611 shares during the period. Aberdeen Asset Management PLC UK raised its stake in shares of Emergent Biosolutions by 7.3% in the 2nd quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock valued at $58,918,000 after acquiring an additional 118,894 shares during the period. Finally, New Amsterdam Partners LLC NY purchased a new stake in shares of Emergent Biosolutions in the 2nd quarter valued at approximately $3,331,000. Institutional investors own 85.33% of the company’s stock.
Shares of Emergent Biosolutions, Inc. (NYSE EBS) opened at 40.08 on Wednesday. The stock has a 50 day moving average of $38.62 and a 200-day moving average of $33.96. Emergent Biosolutions, Inc. has a 1-year low of $24.47 and a 1-year high of $41.46. The stock has a market capitalization of $1.65 billion, a P/E ratio of 25.53 and a beta of 1.26.
Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by ($0.13). Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The company had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. During the same period in the prior year, the business posted ($0.05) earnings per share. Emergent Biosolutions’s revenue was up 10.4% on a year-over-year basis. Equities research analysts predict that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current fiscal year.
In related news, Chairman Fuad El-Hibri sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $40.50, for a total value of $1,012,500.00. Following the sale, the chairman now directly owns 1,555,216 shares of the company’s stock, valued at $62,986,248. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Adam Havey sold 7,885 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $37.06, for a total transaction of $292,218.10. Following the completion of the sale, the executive vice president now directly owns 33,931 shares in the company, valued at $1,257,482.86. The disclosure for this sale can be found here. Insiders sold 230,227 shares of company stock worth $8,793,970 over the last three months. Corporate insiders own 16.50% of the company’s stock.
EBS has been the topic of a number of research analyst reports. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $43.00 price target (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Emergent Biosolutions presently has a consensus rating of “Buy” and a consensus target price of $45.00.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.